undamentalytics Newsletter
Sign in

Compass Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Compass Therapeutics, Inc. had total assets of $220m, total liabilities of $22.8m and shareholders' equity of $197m. It held $30.6m in cash against $0 of debt: net cash of $30.6m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents244331
Total current assets154133210
Total assets157140220
Accounts payable422
Total current liabilities8914
Total debt000
Total liabilities81523
Shareholders' equity149125197
Net debt (negative = net cash)−24−43−31
Shares outstanding128m138m178m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Compass Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Compass Therapeutics, Inc.